Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma
Derek Wong, Ping Luo, Nadia Znassi, Diana P. Arteaga, Diana Gray, Arnavaz Danesh, Ming Han, Eric Y. Stutheit-Zhao, Stephanie Pedersen, Stephenie D. Prokopec, Yogi Sundaravadanam, Dax Torti, Kayla Marsh, Sareh Keshavarzi, Wei Xu, Hatem Krema, Anthony M. Joshua, Marcus O. Butler, Trevor J. Pugh
Abstract
Uveal melanomas are rare tumors arising from melanocytes that reside in the eye. Despite surgical or radiation treatment, approximately 50% of patients with uveal melanoma will progress to metastatic disease, most often to the liver. Cell-free DNA (cfDNA) sequencing is a promising technology due to the minimally invasive sample collection and ability to infer multiple aspects of tumor response. We analyzed 46 serial cfDNA samples from 11 patients with uveal melanoma over a 1-year period following enucleation or brachytherapy (n = ∼4/patient) using targeted panel, shallow whole genome, and cell-free methylated DNA immunoprecipitation sequencing. We found detection of relapse was highly variable using independent analyses (P = 0.06–0.46), whereas a logistic regression model integrating all cfDNA profiles significantly improved relapse detection (P = 0.02), with greatest power derived from fragmentomic profiles. This work provides support for the use of integrated analyses to improve the sensitivity of circulating tumor DNA detection using multi-modal cfDNA sequencing. Significance: Here, we demonstrate integrated, longitudinal cfDNA sequencing using multi-omic approaches is more effective than unimodal analysis. This approach supports the use of frequent blood testing using comprehensive genomic, fragmentomic, and epigenomic techniques.